Special Issue

Emerging Issues in Retinal Degeneration

Message from the Guest Editor

Retinal degeneration includes a spectrum of progressive eye diseases such as age-related macular degeneration (AMD), retinitis pigmentosa (RP) and diabetic retinopathy, all of which can result in significant vision loss or blindness. As the global population ages and diabetes becomes more prevalent, these conditions are emerging as critical public health challenges. This Special Issue is dedicated to showcasing the latest advancements and addressing new challenges in the study of retinal degeneration. We encourage researchers and clinicians to submit original research papers, reviews and case reports that delve into innovative diagnostic techniques, cutting-edge therapeutic strategies and the fundamental molecular pathways involved in retinal degeneration. The areas of interest encompass gene therapy, stem cell therapy, retinal implants and new pharmacological treatments. We also welcome contributions that examine the effects of lifestyle and environmental factors on disease progression, the identification of predictive biomarkers and enhancements in imaging technology.

Guest Editor

Dr. Ponarulselvam Sekar

Department of Ophthalmology, Faculty of Medicine and University Hospital Cologne, University of Cologne, 50937 Cologne, Germany

Deadline for manuscript submissions

31 October 2025

MDPI

Biomedicines

an Open Access Journal by MDPI

**Impact Factor 3.9
CiteScore 6.8
Indexed in PubMed**

About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni
1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:
indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:
JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:
manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).